LSX2026: On a therapeutic vision for ocular disease, with Alexander Gebauer
R&D
At the LSX World Congress in Lisbon this year, web editor Nicole Raleigh stepped aside from the hustle and bustle to speak with Alexander Gebauer, co-founder and executive chairman of Galimedix Therapeutics, a company transforming the treatment of major neurodegenerative diseases of the eye and brain.
Gebauer discusses how amyloid beta plays a role, as well as their lead candidate GAL-101, currently in Phase 2 clinical testing for the treatment of geographic atrophy. He also touches upon what might be next for early-stage life sciences companies looking for investment.
Watch this and other conversations from LSX World Congress and BIO-Europe Spring here.
